Radiopharmaceuticals for targeted radiotherapy of cancer

Bibliography

• VOLKERT WA, HOFFMAN TJ: Therapeutic radiopharma-. Chem. Rev. (1999) 99:2269–2292.
   PubMed Web of Science ®Google Scholar
• •An exhaustive review on therapeutic radionuclides and radiopharmaceuticals for targeted radiotherapy of cancer.
   Google Scholar
• DENARDO GL, DENARDO SJ, MEARES CF et al.: Pharma-cokinetics of copper-67 conjugated Lym-1, A potential therapeutic radioimmunoconjugate, in mice and in patients with lymphoma. Antibodies Immunconj. Radiopharm. (1991) 4:777–785.
   Google Scholar
• BREITZ HB, WEIDEN PL, VANDERHEYDEN JL et al: Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials. J. Nucl. Med. (1992) 33:1099–109.
   PubMed Web of Science ®Google Scholar
• RHODES BA, LAMBERT CR, MAREK MJ, KNAPP FF, HARVEY EB: Re-188 labelled antibodies. Appl. Rad. Isol (1996) 47:7–14.
   PubMed Web of Science ®Google Scholar
• ALVEREZ RD, PARTRIDGE EE, KHAZAELI MB et al: Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a Phase I/II study. Gyn. Oncol (1997) 65:94–101.
   PubMed Web of Science ®Google Scholar
• VAIDYANATHAN G, ZALUTSKY MR: Targeted therapy using alpha emitters. Phys. Med. Biol. (1996) 41:1915–1931.
   PubMed Web of Science ®Google Scholar
• •A review on pharmaceuticals labelled with a emitters with potential utility for treatment of cancer.
   Google Scholar
• ROTMENSCH J, WHITLOCK JL, SCHWARTZ JL, HINES JJ, REBA RC, HARPER PV: In vitro and in vivo studies on the development of the alpha-emitting radionuclide bismuth-212 for intraperitoneal use against microscopic ovarian carcinoma. Am. J. Obs. Gyn. (1997) 176:833–840.
   PubMed Web of Science ®Google Scholar
• KENNEL SJ, MIRZADEH S: Vascular targeted radioimmu-notherapy with Bi-213-an alpha-particle emitter. Nucl. Med. Biol. (1998) 25:241–246.
   PubMed Web of Science ®Google Scholar
• MCCARTHY DW, SHEFER RE, KLINKOWSTEIN RE et al:The efficient production of high specific activity Cu-64 using a biomedical Cyclotron. Nucl. Med. Biol. (1997) 24:35–43.
   PubMed Web of Science ®Google Scholar
• MEARES CF, MOI MK, DIRIL H et al.: Macrocyclic chelates of radiometals for diagnosis and therapy. Br. J. Cancer Suppl. (1990) 10:21–26.
   PubMedGoogle Scholar
• SUBRAMANIAN R, MEARES CF: Bifunctional chelating agents for radiometal-labeled monoclonal antibodies. Kluwer Academic Publishers, New York (1990).
   Google Scholar
• WU C, VIRZI F, HNATOWICH DJ: Investigations of N-linked macrocycles for In-111 and Y-90 labeling of proteins. Nucl. Med. Biol. (1992) 19:239–244.
   Web of Science ®Google Scholar
• PARKER D, PULUKKODY K, NORMAN TJ, HARRISON A, ROYLE L, WALKER C: Stable anionic, neutral and cationic complexes of gadolinium with functionalised amino-phosphinic acid macrocyclic ligands. Chem. Commun. (1992):1441–1443.
   Google Scholar
• GANSOW OA: Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates. Nucl. Med. Biol. (1991) 18:369–381.
   Web of Science ®Google Scholar
• GANSOW OA, BRECHBIEL MW, PIPPIN G, HUNEKE R, SQUIRE P, STRAND M: Synthesis of 2-(p-SCN-benzyl)-trans-cyclohexyl-DTPA (CHX-DTPA); use for alpha particle radioimmunotherapy with Bi-212-MAb-103A in mice infected with the Rauscher leukemia virus. J. Nucl. Med. (1991) 32:1056 (Abstract).
   Google Scholar
• GANSOW OA, BRECHBIEL MW, MIRZADEH S, COLCHER, ROSELLI M: Chelates and antibodies: current methods and new directions. Kluwer Academic Publishers (1990).
   Google Scholar
• GANSOW OA: Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates. Nucl. Med. Biol. (1991) 18:369–381.
   Web of Science ®Google Scholar
• THAKUR ML, KOLAN H, LI J et al.: Radiolabeled somato-statin analogues in prostate cancer. Mid: Med. Biol. (1997) 24:105–113.
   Google Scholar
• SCHUBIGER PA, ALBERTO R, SMITH A: Vehicles, chelators and radionuclides: choosing the 'building blocks' of an effective therapeutic radioimmunoconju-gate. Bioconjugate Chem. (1996) 7:165–175.
   PubMed Web of Science ®Google Scholar
• •An extensive description of the use of bifunctional chelators to attach radiometals to biological molecules (i.e., proteins and peptides).
   Google Scholar
• HNATOWICH DJ, LAYNE WW, CHILDS RL, LANTEIGNE D, DAVIS MA: Radioactive labeling of antibody: A simple and efficient method. Science (1983) 220:613–615.
   PubMed Web of Science ®Google Scholar
• HNATOWICH DJ: Label stability in serum of four radionuclides on DTPA-coupled antibodies-an evalua-tion. Nucl. Med. Biol (1986) 13:353–358.
   Web of Science ®Google Scholar
• BROWN JM: The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain memorial award lecture. Cancer Res. (1999) 59:5863–5870.
   PubMed Web of Science ®Google Scholar
• TANNOCK I, GUTTMAN P: Responses of chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions. Br. J. Cancer (1981) 42:245–248.
   Google Scholar
• TEICHER BA, HOLDEN SA, AL-ACHI SA, HERMAN TS: Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res. (1990) 50:3339–3344.
   PubMed Web of Science ®Google Scholar
• CRABTREE HG, CRAMER W: The action of radium on cancer cells I. II. some factors determining the suscep-tibility of cancer cells to radium. Proc. R. Soc. Ser. B. (1933) 113:238–250.
   Google Scholar
• GRAY LH, CONGER AD, EBERT M, HORNSEY S, SCOTT OC: Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. (1953) 26:638–648.
   PubMed Web of Science ®Google Scholar
• REICHLIN S: Somatostatin (part 1). N Engl. J. Med. (1983) 309:1495–1501.
   PubMedGoogle Scholar
• BAUER W, BRINER U, DOEPFNER W et al: SMS 201-995. Life ScL (1982) 31:1133–1140.
   PubMed Web of Science ®Google Scholar
• BAKKER WH, KRENNING EP, BREEMAN WA et al: In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism and binding to somatostatin receptor-positive tumors in man. J. Nucl. Med. (1991) 32:1184–1189.
   PubMed Web of Science ®Google Scholar
• SMITH-JONES PM, STOLZ B, BRUNS C et al.:Gallium-67/Gallium-68-PF01-octreotide - a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. J. Nucl. Med. (1994) 35:317–325.
   PubMed Web of Science ®Google Scholar
• BAKKER WH, ALBERT R, BRUNS C et al.: [111In-DTPA-D-Phe]-octreotide, a potential radiophar-maceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci. (1991) 49:1583–1591.
   PubMed Web of Science ®Google Scholar
• ••One of the first journal publications describing aradiometal-labelled peptide that specifically bound to the somatostatin receptor.
   Google Scholar
• GUHLKE S, WESTER H-J, BRUNS C, STOCKLIN G:(2418F1Fluoropropionyl-D(Phe1)-Octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: synthesis, radiolabeling, in vitro validation and biodistribution in mice. Nucl. Med. Biol. (1994) 21:819–825.
   PubMed Web of Science ®Google Scholar
• ANDERSON CJ, PAJEAU TS, EDWARDS WB, SHERMAN ELC, ROGERS BE, WELCH MJ: In vitro and in vivo evalua-tion of copper-64-labeled octreotide conjugates. J. Nucl. Med. (1995) 36:2315–2325.
   PubMed Web of Science ®Google Scholar
• OTTE A, MUELLERBRAND J, DELLAS S, NITZSCHE EU, HERRMANN R, MAECKE HR: Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet (1998) 351:417–418.
   PubMed Web of Science ®Google Scholar
• •The first journal publication describing targeted radiotherapy with a KY-labelled somatostatin analogue.
   Google Scholar
• LEIMER M, KURTARAN A, SMITH-JONES P eta].: Response treatment with yttrium-90-DOTA-lanreotide of a patient with metastatic gastrinoma. J. Nucl. Med. (1998) 39:2090–2094.
   Google Scholar
• ZINN KR, BUSH LR, MOUNTZ JM et al: Dose-dependent tumor suppression in nude mice by radiotherapy with Re-188-labeled P829, a somatostatin receptor (SSTR) avid peptide (abstract). J. Nucl. Med. (1999) 40:223P.
   Web of Science ®Google Scholar
• SAID SI: Vasoactive intestinal peptide. Raven Press, New York (1982).
   Google Scholar
• PRIETO JC, LABURTHE M, ROSSELIN G: Interaction of VIP with isolated intestinal epithelial cells from rat. J. Biochem. (1979) 96:229–234.
   Web of Science ®Google Scholar
• BLUM AM, MATHEW R, COOK GA, METWALI A, FELMANR, WEINSTOCK JV: Murine mucosal T cells have VIP receptors functionally distinct from those on intestinal epithelial cells. J. NeuroimmunoL (1982) 39:101–108.
   Google Scholar
• PAUL S, SAID SI: Characterization of receptors forvasoactive intestinal peptide solubilized from the lung. J. Biol. Chem. (1987) 262:158–162.
   PubMed Web of Science ®Google Scholar
• VIRGOLINI I, RADERER M, KURTARAN AQ et al.: Vasoac-tive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. /V. Eng/. J. Med. (1994) 331:1116–1121.
   PubMed Web of Science ®Google Scholar
• VIRGOLINI I, KURTARAN A, RADERER M et al.: Vasoactiveintestinal peptide receptor scintigraphy. J. Nucl. Med. (1995) 36:1732–1739.
   PubMed Web of Science ®Google Scholar
• RADERER M, KURTARAN A, YANG Q et al.: Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer. J. Nucl. Med. (1998) 39:1570–1575.
   PubMed Web of Science ®Google Scholar
• THAKUR ML, MARCUS CS, SAEED S et al: 99mTc-labeledvasoactive intestinal peptide analog for rapid localiza-tion of tumors in humans. J. Nucl. Med. (2000) 41:107–110.
   PubMed Web of Science ®Google Scholar
• JACKSON S, DEGRADO W, DWIVEDI A et al. Templateconstrained cyclic peptides: design of high-affinity ligands for GPIIb/IIIa. J. Am. Chem. Soc. (1989) 116:3220–3230.
   Google Scholar
• KOMORIYA A, GREEN LJ, MERVIC M, YAMADA SS, YAMADA KM, HUMPHRIES MJ: The minimal essential sequence for a major cell type-specific adhesion site (CS1) within the alternatively spliced type III connecting domain of fibronectin is leucine-aspartic acid-valine. J. Biol. Chem. (1991) 266:15075–15079.
   PubMed Web of Science ®Google Scholar
• AX WORTHY DB, RENO JM, HYALARIDES MD et al.: Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. USA (2000) 97:1802–1807.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive study of the NeoRx 90Y-labelledpre-targeting strategy that accomplished complete cures of tumours in mice.
   Google Scholar
• KNOX SJ, GORIS ML, TEMPERO M et al.: Phase II trial of-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin. Cancer Res. (2000) 6:406–414.
   PubMed Web of Science ®Google Scholar
• •The clinical trial of the NeoRx 90Y-labelled pre-targeting agent in patients with colon cancer.
   Google Scholar
• GOODWIN DA, MEARES CF, MCCALL MJ, MCTIGUE M, CHAOVAPONG W: Pre-targeted immunoscintigraphy of murine tumors with In-111-labeled bivalent haptens. j Nucl. Merl. (1988) 29:226–334.
   Google Scholar
• GOODWIN DA, MEARES CF, MCTIGUE M et al.: Pre-targeted immunoscintigraphy: effect of hapten valency on murine tumor uptake. J. Nod Merl. (1992) 33:2006–2013.
   Google Scholar
• GOODWIN DA, MEARES CF, WATANABE N et al: Pharma-cokinetics of Pre-targeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(P-Nitrobenzy1)-1,4,7,10 -tetraazacyclododecanetetraacetic acid (DOTA) in BALB/C mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy. Cancer Res. (1994) 54:5937–5946.
   Google Scholar
• KLIVENYI G, SCHUHMACHER J, PATZELT E et al.:Gallium-68 chelate imaging of human colon carcinoma xenografts pretargeted with bispecific anti-CD44v6/anti-gallium chelate antibodies. J. Nucl. Med. (1998) 39:1769–1776.
   PubMed Web of Science ®Google Scholar
• KRANENBORG MHGC, BOERMAN OC, GRIFFITHS GL etal.: Two-step targeting of rcc tumors in mice: improved tumor uptake and retention with a bivalent chelate (abstract). J. Nucl. Merl. (1998) 39:78P.
   Google Scholar
• KRANENBORG MHGC, BOERMAN OC, OOSTERWIJK-WAKKA JC et al.: Two-step radio-immunotargeting of renal-cell carcinoma xenografts in nude mice with anti-renal-cell-carcinoma X anti-DTPA bispecific monoclonal antibodies. Int. J. Cancer (1998) 75:74–80.
   PubMed Web of Science ®Google Scholar
• VUILLEZ JP, MORO D, BRICHON PY et al. Two-step For non-small-cell lung cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J. Nucl. Med. (1997) 38:507–511.
   PubMed Web of Science ®Google Scholar
• BARBET J, PELTIER P, BARDET S et al.: Radioimmunode-tection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA X anti-DTPA-indium bispecific antibody. J. Nod Merl. (1998) 39:1172–1178.
   Google Scholar
• BROWNE E, DAIRIKI JM, DOEBLER RE: Table of Isotopes, Seventh Edition. Lederer CM, Shirley VS (Eds.), Wiley Interscience, New York, USA (1978).
   Google Scholar